1.82
+4.60%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Oncopeptides
Its shares trade on Nasdaq Stockholm under the ticker ONCO.ST. It has been listed since 22 February 2017. In the fiscal year to 31 December 2025, it reported revenue of SEK 71.1m and a net loss of SEK 249.6m. At that date it held total assets of SEK 134.8m and shareholders' equity of −SEK 58.9m.
Oncopeptides AB is a pharmaceutical company focused on the development of targeted therapies for hematological diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2017-02-22. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Feb 2017
- Employees
- 232
- Website
- oncopeptides.se ↗
Leadership
Pay as last reported
- Mr. Per Wold-OlsenIndependent Chairman of the BoardSEK 1.7m
- Ms. Sofia HeigisChief Executive OfficerSEK 7.9m
- Mr. Henrik BergentoftChief Financial Officer
- Ms. Eva NordstromChief Operating Officer, Deputy Managing Director
- Mr. David AugustssonDirector of Corporate Affairs
- Ms. Lotta LarssonHead of Human Resources
- Mr. Stefan NorinChief Medical Officer
- Mr. Per SamuelssonDirectorSEK 368,000
- Ms. Christine RankinIndependent Director
- Mr. Brian StuglikIndependent DirectorSEK 772,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 65
- Environment
- 18
- Social
- 99
- Governance
- 78
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Oncopeptides AB is a leading biotech company specializing in the development of targeted therapies for patients with hematological cancers.
- The company's flagship product, melflufen, has shown promising results in clinical trials, demonstrating its potential to improve outcomes for patients with multiple myeloma.
- Oncopeptides has a strong intellectual property portfolio, providing a competitive advantage and protecting their innovative therapies from potential competitors.
- The company has an experienced management team with expertise in drug development, ensuring effective decision-making and strategic planning.
Weaknesses
- Oncopeptides heavily relies on the success of melflufen, with limited product diversification in their pipeline.
- The company is in the early stages of commercializing their products, which presents challenges in terms of revenue generation and market penetration.
- As a biotech company, Oncopeptides faces significant regulatory and clinical trial risks, which may lead to delays or failures in product development and approval.
- The company's financial resources might be limited, requiring external funding sources to support ongoing research and development efforts.
Opportunities
- The global market for targeted therapies in hematological cancers is growing rapidly, providing a significant opportunity for Oncopeptides to capture market share and generate substantial revenue.
- Expanding the product portfolio through strategic partnerships or licensing agreements could help diversify Oncopeptides' offerings and optimize revenue streams.
- Advancements in personalized medicine and genomic profiling create opportunities for Oncopeptides to develop customized therapies tailored to individual patients, enhancing treatment effectiveness.
- Collaborating with leading research institutions and key opinion leaders can further strengthen the company's position in the biotech industry and facilitate knowledge exchange.
Threats
- Intense competition within the biotech industry presents a threat to Oncopeptides' market share and pricing power, potentially impacting their ability to generate sustainable profitability.
- Emerging market entrants and disruptive technologies could challenge Oncopeptides' existing product offerings and render them less competitive in the rapidly evolving landscape.
- Regulatory uncertainties and evolving reimbursement policies can create barriers to market entry and affect the company's pricing and profitability.
- Unexpected adverse events or safety concerns during clinical trials or post-approval stages can lead to regulatory setbacks, loss of public trust, and reputational damage.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.